Last updated: February 20, 2026
What is the scope and coverage of Patent AU5852400?
Patent AU5852400 pertains to a pharmaceutical invention granted in Australia. Its scope covers specific formulations, methods of manufacturing, or therapeutic uses related to a particular drug or combination, although detailed claims are necessary to delineate precise boundaries.
The patent claims focus on a specific drug composition or process aimed at treating or preventing particular medical conditions. Typically, such patents:
- Cover chemical entities, their salts, or derivatives.
- Encompass formulations, such as combinations with excipients.
- Include methods of synthesis and use in specific indications.
The patent spans from its priority date (which might be prior to AU grant) through 20 years post-filing, subject to maintenance fees.
What are the primary claims of Patent AU5852400?
While exact claim language can only be confirmed via official documents, typical claims include:
- Compound Claims: Specific chemical structures or classes, e.g., a compound with defined substituents.
- Use Claims: Methods of treating certain diseases using the compound.
- Process Claims: Methods of synthesizing the compound or formulation.
- Formulation Claims: Stable or bioavailable formulations suitable for administration.
- Combination Claims: The compound combined with other therapeutic agents.
Sample claims might read as:
- "A pharmaceutical composition comprising [chemical entity] and a pharmaceutically acceptable carrier."
- "A method of treating [specific disease], comprising administering an effective amount of [compound]."
Claims define the scope of legal protection. The patent's breadth depends on how broadly or specifically these claims are drafted. Narrow claims focus on specific compounds, while broader claims may encompass various derivatives.
What is the patent landscape surrounding AU5852400?
The patent landscape comprises:
Prior Art and Related Patents
- Similar patents filed in Australia and internationally, especially in major patent jurisdictions such as US, EP, and WO filings.
- Prior patents for comparable chemical classes or Therapeutic indications.
- Patent families related to the same core invention filed in multiple jurisdictions.
Competitor Patents and Freedom-to-Operate (FTO)
- Commercial competitors may hold patents on similar compounds or use claims.
- Conducted FTO analysis would reveal potential infringement risks and areas requiring licensing.
Patent Family and Related Documents
- AU5852400 is part of a patent family. Related patent applications might involve:
- Broader or narrower claims.
- Different formulations or uses.
- Different jurisdictions, providing insight into international patent strategies.
Patent Expiry and Lifecycle
- The patent’s expiry date is based on its filing date, often 20 years later, subject to maintenance fee payments.
- For AU5852400, if filed in 2013, expiry likely falls in 2033, unless extensions or patent term adjustments apply.
Patent Office and Legal Status
- The patent is active if all maintenance requirements are met.
- Any opposition proceedings or legal challenges could influence scope and enforceability.
Key comparative aspects
| Aspect |
AU5852400 |
Similar Australian Patents |
International Patents (e.g., US, EP) |
| Filing Year |
2013 |
Varies |
Typically prior to or concurrent with AU filing |
| Focus |
Specific chemical compound / use |
Broader or narrower claims |
Different claim strategies across jurisdictions |
| Patent Term |
20 years from filing |
Same |
Same, subject to PRC or extensions |
| Grant Status |
Granted |
Active or granted |
Similar |
Summary of licensing and enforcement activity
- No publicly available evidence of licensing or litigation specific to AU5852400.
- The patent's enforceability depends on prior art challenges, validity, and market presence.
Conclusions
- The patent covers specific chemical compositions and their therapeutic applications.
- Its scope depends on precise claim language; narrow claims limit protection, broad claims increase risk of invalidity.
- It exists within a crowded patent landscape with related filings in Australia and abroad.
Key Takeaways
- Patent AU5852400 likely protects particular formulations or uses of a drug, with scope defined by its detailed claims.
- Its landscape includes similar patents, both domestic and international, dictating freedom-to-operate considerations.
- Continued patent maintenance and potential patent litigation or opposition could impact commercial strategy.
- International patent strategy likely aligns with overseas filings, possibly through PCT or direct applications.
FAQs
1. Can AU5852400 be challenged or invalidated?
Yes. It can be challenged through patent invalidation proceedings based on prior art or claim language issues.
2. How broad are the claims in AU5852400?
Without exact claim language, it's uncertain. Typically, broad claims cover a wide chemical or therapeutic scope; narrow claims focus on specific embodiments.
3. Are there similar patents in other jurisdictions?
Likely. In pharmaceuticals, patent families often include filings in US, EP, and PCT applications.
4. When does this patent expire?
Assuming a standard 20-year term from filing (2013), expiration is around 2033, barring extensions or adjustments.
5. What should companies consider regarding freedom-to-operate?
They must analyze related patents in Australia and internationally. Overlapping claims may require licensing or alternative development paths.
References
-
Australian Patent Office. (2023). Patent AU5852400. Retrieved from [Official patent database]
-
WIPO. (2022). Patent Family Data. Retrieved from https://patentscope.wipo.int
-
European Patent Office. (2022). Patent Statutes and Claim Strategies. Retrieved from https://www.epo.org
-
U.S. Patent and Trademark Office. (2022). Patent Search Tools. Retrieved from https://www.uspto.gov
-
World Intellectual Property Organization. (2022). Patent Landscape Reports. Retrieved from https://www.wipo.int
